Aging and Longevity
2005; Lippincott Williams & Wilkins; Volume: 97; Issue: 5 Linguagem: Inglês
10.1161/01.res.0000182212.09147.56
ISSN1524-4571
Autores Tópico(s)GDF15 and Related Biomarkers
ResumoHomeCirculation ResearchVol. 97, No. 5Aging and Longevity Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBAging and LongevityThe IGF-1 Enigma Piero Anversa Piero AnversaPiero Anversa From the Cardiovascular Research Institute, Department of Medicine, New York Medical College, Valhalla. Originally published2 Sep 2005https://doi.org/10.1161/01.RES.0000182212.09147.56Circulation Research. 2005;97:411–414IGF-1 belongs to the insulin family of peptides and acts as a growth factor in many tissues and tumors. Locally acting isoform of IGF-1 targeted to skeletal muscle enhances muscle growth and differentiation, prevents age-related muscle atrophy, and potentiates regeneration after injury.1,2 Similarly, cardiac restricted expression of IGF-1 increases the formation of ventricular myocytes, attenuates myocyte death, and delays the development of an aging myopathy.3,4 In the heart, the IGF-1–IGF-1 receptor system induces division of cardiac stem cells (CSCs), upregulates telomerase activity, hinders replicative senescence, and preserves the pool of functionally competent CSCs.4,5 After muscle injury, IGF-1 promotes the activation, mobilization, and differentiation of satellite cells which, together with the recruitment of bone marrow progenitor cells, contribute to skeletal muscle regeneration in old animals.1,2 Spontaneous repair of damaged muscle typically occurs in young animals and is severely impaired with age. Importantly, heart failure leads to a catabolic state characterized by a progressive loss in skeletal muscle mass and the appearance of cardiac cachexia in the late stages of the disease. This information formed the basis of the study by Schulze et al6 published in the current issue of Circulation Research.The dramatic problem of skeletal muscle wasting with chronic heart failure has become a common clinical reality. Cardiac decompensation is a disease of the elderly, which has reached endemic proportion with the progressive increase in average lifespan of the population in the Western world.7 Unfortunately, muscle atrophy cannot easily be reversed, and the pharmacology is palliative at best. Similarly, strategies aiming at the reconstitution of muscle mass with systemic administration of growth factors or potential implementation of cell therapy are in an infancy stage. The work of Schulze et al has addressed this major pathological condition with a novel molecular–genetic approach based on the recognition of a signaling pathway that involves the ubiquitin–proteasome complex.6 Remarkably, the upstream positive modulator of the muscle-specific ubiquitin ligase atrogin-1/MAFbx has been identified in the Foxo transcription factors (Figure 1). Upregulation of Foxo opposes the synthesis of muscle proteins,8 which is, however, counteracted by a selective muscle isoform of IGF-1 through phosphorylation of Foxo by Akt and inhibition of Foxo transcriptional activity.6 In both skeletal muscle and heart, IGF-1 activates the PI3-kinase pathway that in turn phosphorylates Akt targeting several molecules promoting cell growth and survival.9 Prevention of cell death and induction of cell replication are the ultimate goal of cell therapy; the former attenuates the extent of injury, and the latter determines the degree of structural and functional recovery. Download figureDownload PowerPointFigure 1. Schematic representation of the effects of mIGF-1 on muscle growth.The IGF-1–IGF-1 receptor system plays an important role not only in skeletal and cardiac muscle disease but also in organism development. Homozygous deletion of IGF-1 in mice does not preclude embryonic and fetal formation of organs but offspring body weight is 45% of wild-type littermates, suggesting that IGF-1 controls >50% of body mass.10 More dramatic are the effects of targeted disruption of the IGF-1 receptor gene. Generalized organ hypoplasia with respiratory failure occurs, and these defects lead invariably to death at birth.10 Paradoxically, mutation of the homologue of insulin–IGF-1 receptor, daf-2 in nematodes or Inr in fruit flies, delays aging and extends maximum lifespan in these lower eukaryotes.11 Attenuation of insulin/IGF-1 signaling results in upregulation of DAF-16 which activates a variety of genes implicated in longevity and inhibits selective life-shortening genes.12 Conversely, as elegantly demonstrated by Schulze et al,6 overexpression of muscle IGF-1 interferes with Foxo, which is the mammalian homolog of DAF-16, and inactivation of Foxo has a powerful positive therapeutic impact on skeletal muscle growth and cachexia. How important these differences are in distal effectors of insulin/IGF-1 between invertebrates and mammals is difficult to appreciate, but caution against the tendency to translate results in worms and flies to human beings. Restoration of IGF-1 levels in elderly individuals by hormone-replacement therapy has significant health benefits.13The molecular mechanism underlying the increased lifespan in long-lived daf-2 mutants is largely mediated by the enhanced expression of enzymes that protect and repair oxidative damage.12 Reactive oxygen species (ROS) are formed in several compartments of the cells, but ≈90% of intracellular oxidants is generated within the mitochondria. Strong reductions in IGF-1 signaling in C. elegans results in a quiescent state of diapause called dauer, which corresponds to a nonfeeding stress-resistant larval state.11 Most importantly, nearly 35% of nematodes with modest decreases in daf-2 become extremely lethargic and dauer-like and lose spontaneous motility. In both cases, oxidative stress is minimal and longevity may be dictated by the metabolic switch.14 This possibility is consistent with the well-established paradigm of extended lifespan with severe caloric restriction or reduced fat mass in lower organisms and mammals.15,16 In yeasts, dietary limitation promotes metabolic changes that invariably increase maximum lifespan.17 The low metabolic state is regulated by Sir2 that may be part of the IGF-1 pathway.18 The question is whether the IGF-1–IGF-1 receptor system has to be blamed as the cause of premature aging and death in yeasts, nematodes, fruit flies, and mammals, or oxidative stress is a more likely determinant of longevity, supporting the notion of the free radical theory of aging.The increase in lifespan, albeit modest, of mice heterozygous for the deletion of the IGF-1 receptor is restricted to the female cohort, and the lack of evidence in males remains unexplained.19 Similarly, the few hour increase in survival of transgenic mice after the injection of paraquat to induce oxidative damage is a weak argument in favor of the deleterious effects of IGF-1 receptors on oxidative stress response and life expectancy. In the Western world, women live several years longer than men do and have a reduced incidence of heart failure, but the underlying cause for this difference in lifespan between genders is currently unknown.7 Importantly, the female heart is more resistant to aging effects than the male heart and has an enhanced expression and nuclear localization of Akt,20 powerful survival factor and distal effector of IGF-1. Animal models with deficiencies in IGF-1 are complicated by the concurrent alterations in growth hormone or hypopituitarism, which result in multiple endocrine defects and developmental abnormalities.13 These confounding factors make the dwarf mice inappropriate for the assessment of the role of IGF-1 in biological aging and lifespan.13Targeted mutation of the p66shc gene decreases the formation of ROS, increases the resistance to oxidative stress, and prolongs life by 30% in mice.21 This constitutes the first demonstration that a gene can modify the formation and effects of ROS on survival and maximum lifespan in mammals. By multiple pathways, p53 increases the intracellular concentration of ROS. The adaptor protein p66shc constitutes a powerful effector that links p53 to oxidative stress. In the absence of p53, the ability of p66shc to modulate the elevation of intracellular oxidants and induce cell death is lost.22 p66shc possesses a unique N-terminal domain that becomes phosphorylated at Ser 36 when cells are exposed to oxidative stress. Phosphorylated p66shc inhibits the activity of the forkhead family of transcription factors (Foxo), leading to the reduced transcription of forkhead target genes such as the antioxidants superoxide dismutase and catalase.23 Additionally, a fraction of intracellular p66shc is located within the mitochondria where it binds to the heat shock protein, Hsp70. This inert complex is activated and dissociated on oxidative stress, leading to a marked decrease in mitochondrial membrane potential and increased transmitochondrial permeability and ROS formation.22 In this regard, it has recently been shown that overexpression of catalase targeted to the mitochondria expands median and maximum lifespan in mice.24 IGF-1 downregulates p53 and Bax and upregulates Bcl2 in cardiomyocytes.25 p53 is a potent stimulant of Ang II formation which, in turn, increases cytosolic calcium and oxidative stress leading to cellular senescence and death. Whether a similar mechanism is operative in skeletal muscle is currently unknown. But, if this were the case, it could contribute to the prevention of muscle atrophy observed by Schulze et al in chronic heart failure.6Recent studies in mice have indicated that p53 activation by overexpression of p44 leads to premature organism aging by an adaptive compensatory response characterized by upregulation of the IGF-1–IGF-1 receptor system.26,27 p44 is a short isoform of p53 with a truncation of the amino-terminal of p53. Because Mdm2 binds to the amino-terminal of p53, p44 is no longer modulated by Mdm2. The unusual role of p53 in accelerating the aging process through the IGF-1 signaling pathway is at variance with findings concerning the impact of IGF-1 on p53. IGF-1 phosphorylates the amino terminal of p53 and, thereby, the expression of Mdm2. Mdm2 binds to p53 leading to the formation of Mdm2–p53 inactive complexes and inhibition of p53 function.25The postulated negative role of IGF-1 in life expectancy contrasts with the positive effects of IGF-1 on skeletal muscle atrophy and cardiomyocyte loss as a function of age in mice. Some clues to this conundrum are found in the study of Schulze et al. IGF-1 increases the anabolism of skeletal muscle cells and attenuates the ubiquitin–proteasome pathway and, therefore, muscle catabolism and the formation of oxidative products with heart failure.6 Similarly, IGF-1 decreases oxidative damage in the myocardium with aging4 and diabetes in vivo and hyperglycemia in vitro (PA, unpublished data, 2005). IGF-1 prevents downregulation of the uncoupling protein-3 with hyperglycemia, interfering with the generation of ROS,28 and can repair oxidative DNA damage by homologous recombination.29 Importantly, IGF-1 decreases baseline production of ROS and prevents DNA damage, irreversible growth arrest and apoptotic death of adult CSCs (Figure 2), and a similar phenomenon may be operative in skeletal muscle stem cells.1Download figureDownload PowerPointFigure 2. Cardiac progenitor cells and reactive oxygen species. A and B, Baseline formation of hydroxyl radicals (green) in isolated c-kit positive progenitor cells in the absence (A) and in the presence (B) of IGF-1 at 100 ng/mL. Hydrogen peroxide, 100 μmol/L, markedly increases the generation of hydroxyl radicals (C) which is significantly reduced by IGF-1 (D). Nuclei are stained by Syto17 (red).The short lifespan in lower organisms such as the C. elegans and the Drosophila is linked to the loss of regenerative capacity of somatic tissues in adulthood.30 Dying cells cannot be replaced, and this results in a rapid and progressive decline in organ function. Conversely, cell turnover by activation and commitment of resident progenitor cells remains active in mammals, and old damaged cells that accumulate with time can be replaced by new, younger, better functioning cells. IGF-1 potentiates cell turnover and regeneration in susceptible cells including CSCs5 and satellite cells.1,2 Skeletal muscle and myocardial regeneration mediated by IGF-1 activation and growth of satellite cells and CSCs delays the onset of heart failure and its complications in mammals.1,2,4–6 However, the impact of IGF-1 on aged terminally differentiated cells is more complex and only partially understood. The growth stimulating IGF-1 signals may be substituted by metabolic insulin signals31 that enhance oxidative stress and might trigger the endogenous cell death pathway.In summary, the postulated aging effects of IGF-1 are not clear. Human studies indicate that increased levels of IGF-1 are characterized by a decreased incidence of heart failure and mortality in elderly individuals.32,33 This impact of IGF-1 on the human heart may be operative at the level of the CSC compartment where primitive cells continue to renew themselves and give rise to committed progenies. Similarly, the skeletal muscle–specific IGF-1 isoform may counteract the decline in mass and functional performance with old age and ventricular decompensation, protecting the pool of satellite cells which effectively replace senescent dying cells.1,2,6 Together, these observations support the hypothesis that well-preserved functional CSCs and skeletal muscle satellite cells maintain the youth of the heart and skeletal muscle opposing aging effects and disease states. Extreme caution has to be exercised in the translation of results in simple postmitotic organisms to large mammals and particularly human beings in which the life and death of most somatic organs is regulated by a stem cell compartment.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.This work was supported by grants from the National Institutes of Health.FootnotesCorrespondence to Piero Anversa, MD, Cardiovascular Research Institute, Vosburgh Pavilion, New York Medical College, Valhalla, NY 10595. E-mail [email protected] References 1 Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001; 27: 195–200.CrossrefMedlineGoogle Scholar2 Musaro A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, Cairns L, Ottolenghi G, Cossu G, Bernardi G, Battistini L, Molinaro M, Rosenthal N. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci U S A. 2004; 101: 1206–1210.CrossrefMedlineGoogle Scholar3 Reiss K, Cheng W, Ferber A, Kajstura J, Li P, Li B, Olivetti G, Homcy CJ, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci U S A. 1996; 93: 8630–8635.CrossrefMedlineGoogle Scholar4 Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi I, Zias E, Walsh K, Rosenzweig A, Sussman MA, Urbanek K, Nadal-Ginard B, Kajstura J, Anversa P, Leri A. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res. 2004; 94: 514–524.LinkGoogle Scholar5 Linke A, Muller P, Nurzynska D, Casarsa C, Torella D, Nascimbene A, Castaldo C, Cascapera S, Bohm M, Quaini F, Urbanek K, Leri A, Hintze TH, Kajstura J, Anversa P. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infracted myocardium, improving cardiac function. Proc Natl Acad Sci U S A. 2005; 102: 8966–8971.CrossrefMedlineGoogle Scholar6 Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, Lee RT, Rosenthal N. Transgenic overexpression of locally acting IGF-1 inhibits ubiquitin-mediated muscle atrophy in chronic left ventricular dysfunction. Circ Res. 2005; 97: 418–426.LinkGoogle Scholar7 Sanderson WC, Scherbov S. Average remaining lifetimes can increase as human populations age. Nature. 2005; 435: 811–813.CrossrefMedlineGoogle Scholar8 Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004; 117: 399–412.CrossrefMedlineGoogle Scholar9 Sussman MA, Anversa P. Myocardial aging and senescence: where have the stem cells gone? Annu Rev Physiol. 2004; 66: 29–48.CrossrefMedlineGoogle Scholar10 Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993; 75: 59–72.MedlineGoogle Scholar11 Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science. 2003; 299: 1346–1351.CrossrefMedlineGoogle Scholar12 Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J, Li H, Kenyon C. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature. 2003; 424: 277–283.CrossrefMedlineGoogle Scholar13 Carter CS, Ramsey MM, Sonntag WE. A critical analysis of the role of growth hormone and IGF-1 in aging and lifespan. Trends Genet. 2002; 18: 295–301.CrossrefMedlineGoogle Scholar14 Arantes-Oliveira N, Berman JR, Kenyon C. Healthy animals with extreme longevity. Science. 2003; 302: 611.CrossrefMedlineGoogle Scholar15 Kenyon C. A conserved regulatory system for aging. Cell. 2001; 105: 165–168.CrossrefMedlineGoogle Scholar16 Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003; 299: 572–574.CrossrefMedlineGoogle Scholar17 Kenyon C. The plasticity of aging: insights from long-lived mutants. Cell. 2005; 120: 449–460.CrossrefMedlineGoogle Scholar18 Guarente L, Picard F. Calorie restriction - the SIR2 connection. Cell. 2005; 120: 473–482.CrossrefMedlineGoogle Scholar19 Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le Bouc Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003; 421: 125–126.CrossrefMedlineGoogle Scholar20 Camper-Kirby D, Welch S, Walker A, Shiraishi I, Setchell KD, Schaefer E, Kajstura J, Anversa P, Sussman MA. Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res. 2001; 88: 1020–1027.CrossrefMedlineGoogle Scholar21 Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci PG. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature. 1999; 402: 309–313.CrossrefMedlineGoogle Scholar22 Pelicci G, Dente L, De Giuseppe A, Verducci-Galletti B, Giuli S, Mele S, Vetriani C, Giorgio M, Pandolfi PP, Cesareni G, Pelicci PG. A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. Oncogene. 1996; 13: 633–641.MedlineGoogle Scholar23 Ravichandran KS. Signaling via Shc family adapter proteins. Oncogene. 2001; 20: 6322–6330.CrossrefMedlineGoogle Scholar24 Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, Coskun PE, Ladiges W, Wolf N, Van Remmen H, Wallace DC, Rabinovitch PS. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science. 2005; 308: 1909–1911.CrossrefMedlineGoogle Scholar25 Leri A, Liu Y, Wang X, Kajstura J, Malhotra A, Meggs LG, Anversa P. Overexpression of insulin-like growth factor-1 attenuates the myocyte renin-angiotensin system in transgenic mice. Circ Res. 1999; 84: 752–762.CrossrefMedlineGoogle Scholar26 Tyner SD, Venkatachalam S, Chol J, Jones S, Ghebranlous N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Park SH, Thompson T, Karsenty G, Bradley A, Donehower LA. P53 mutant mice that display early ageing-associated phenotypes. Nature. 2002; 415: 45–53.CrossrefMedlineGoogle Scholar27 Campisi J. Fragile fugue: p53 in aging, cancer and IGF signaling. Nature Med. 2004; 10: 231–232.CrossrefMedlineGoogle Scholar28 Gustafsson H, Soderdahl T, Jonsson G, Bratteng JO, Forsby A. Insulin-like growth factor type 1 prevents hyperglycemia-induced uncoupling protein 3 down-regulation and oxidative stress. J Neurosci Res. 2004; 77: 285–291.CrossrefMedlineGoogle Scholar29 Yang S, Chintapalli J, Sodagum L, Baskin S, Malhorta A, Reiss K, Meggs LG. Activated IGF-1R inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination. Am J Physiol Renal Physiol. 2005;Epub ahead of print.Google Scholar30 Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M, Scrable H. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 2004; 18: 306–319.CrossrefMedlineGoogle Scholar31 Dupont J, Holzenberger M. Biology of insulin-like growth factors in development. Birth Defects Res C Embryo Today. 2003; 69: 257–271.CrossrefMedlineGoogle Scholar32 Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, Levy D, Wilson PWF. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: The Framingham Heart Study. Ann Intern Med. 2003; 139: 642–648.CrossrefMedlineGoogle Scholar33 Roubenoff R, Parise H, Payette HA, Abad LW, D'Agostino R, Jacques PF, Wilson PWF, Dinarello CA, Harris TB. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community dwelling men and women: The Framingham Heart Study. Am J Med. 2003; 115: 429–435.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Aronow W and Frishman W (2020) Cardiac Disease in Older Adults Principles and Practice of Geriatric Surgery, 10.1007/978-3-319-47771-8_15, (229-249), . Yurova M, Tyndyk M, Popovich I, Golubev A and Anisimov V (2019) Gender Specificity of the Effect of Neonatal Melatonin Administration on Lifespan and Age-Associated Pathology in 129/Sv Mice, Advances in Gerontology, 10.1134/S2079057019030184, 9:3, (317-326), Online publication date: 1-Jul-2019. Anisimov V, Labunets I, Popovich I, Tyndyk M, Yurova M and Golubev A (2019) In mice transgenic for IGF1 under keratin-14 promoter, lifespan is decreased and the rates of aging and thymus involution are accelerated, Aging, 10.18632/aging.101903, 11:7, (2098-2110), Online publication date: 13-Apr-2019. Aronow W and Frishman W (2018) Cardiac Disease in Older Adults Principles and Practice of Geriatric Surgery, 10.1007/978-3-319-20317-1_15-1, (1-21), . Ben-Avraham D, Govindaraju D, Budagov T, Fradin D, Durda P, Liu B, Ott S, Gutman D, Sharvit L, Kaplan R, Bougnères P, Reiner A, Shuldiner A, Cohen P, Barzilai N and Atzmon G (2017) The GH receptor exon 3 deletion is a marker of male-specific exceptional longevity associated with increased GH sensitivity and taller stature, Science Advances, 10.1126/sciadv.1602025, 3:6, Online publication date: 2-Jun-2017. Shirakabe A, Ikeda Y, Sciarretta S, Zablocki D and Sadoshima J (2016) Aging and Autophagy in the Heart, Circulation Research, 118:10, (1563-1576), Online publication date: 13-May-2016. Ren J and Anversa P (2015) The insulin-like growth factor I system: Physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome, Biochemical Pharmacology, 10.1016/j.bcp.2014.12.006, 93:4, (409-417), Online publication date: 1-Feb-2015. Sharples A, Hughes D, Deane C, Saini A, Selman C and Stewart C (2015) Longevity and skeletal muscle mass: the role of IGF signalling, the sirtuins, dietary restriction and protein intake, Aging Cell, 10.1111/acel.12342, 14:4, (511-523), Online publication date: 1-Aug-2015. Papatheodorou S, Rohrmann S, Lopez D, Bradwin G, Joshu C, Kanarek N, Nelson W, Rifai N, Platz E and Tsilidis K (2014) Association between endogenous sex steroid hormones and insulin-like growth factor proteins in US men, Cancer Causes & Control, 10.1007/s10552-013-0336-4, 25:3, (353-363), Online publication date: 1-Mar-2014. Ibarra C, Vicencio J, Estrada M, Lin Y, Rocco P, Rebellato P, Munoz J, Garcia-Prieto J, Quest A, Chiong M, Davidson S, Bulatovic I, Grinnemo K, Larsson O, Szabadkai G, Uhlén P, Jaimovich E and Lavandero S (2012) Local Control of Nuclear Calcium Signaling in Cardiac Myocytes by Perinuclear Microdomains of Sarcolemmal Insulin-Like Growth Factor 1 Receptors, Circulation Research, 112:2, (236-245), Online publication date: 18-Jan-2013. Maggio M, Cattabiani C, Lauretani F, Bandinelli S, De Vita F, Dall'Aglio E, Corsonello A, Lattanzio F, Paolisso G, Ferrucci L and Ceda G (2013) Insulin-Like Growth Factor-1 Bioactivity Plays a Prosurvival Role in Older Participants, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 10.1093/gerona/glt045, 68:11, (1342-1350), Online publication date: 1-Nov-2013. Jong H, Mustafa M, Vanhoutte P, AbuBakar S and Wong P (2013) MicroRNA 299-3p modulates replicative senescence in endothelial cells, Physiological Genomics, 10.1152/physiolgenomics.00071.2012, 45:7, (256-267), Online publication date: 1-Apr-2013. Musarò A (2012) To the heart of the problem. mIGF-1: local effort for global impact, Aging, 10.18632/aging.100466, 4:6, (377-378), Online publication date: 23-Jun-2012. Padín-Iruegas M and López López R (2012) Stem Cells as a Tool for Breast Imaging, Journal of Oncology, 10.1155/2012/814014, 2012, (1-7), . Li J and Pei M (2012) Cell Senescence: A Challenge in Cartilage Engineering and Regeneration, Tissue Engineering Part B: Reviews, 10.1089/ten.teb.2011.0583, 18:4, (270-287), Online publication date: 1-Aug-2012. (2012) Insulin and Insulin‐Like Growth Factor Metabolic Syndrome and Cardiovascular Disease, 10.1002/9781118480045.ch5, (96-119), Online publication date: 29-Aug-2012. Friedrich N, Schneider H, Haring R, Nauck M, Völzke H, Kroemer H, Dörr M, Klotsche J, Jung-Sievers C, Pittrow D, Lehnert H, März W, Pieper L, Wittchen H, Wallaschofski H and Stalla G (2012) Improved prediction of all-cause mortality by a combination of serum total testosterone and insulin-like growth factor I in adult men, Steroids, 10.1016/j.steroids.2011.10.005, 77:1-2, (52-58), Online publication date: 1-Jan-2012. Hu J, Li C, Wang L, Zhang X, Zhang M, Gao H, Yu X, Wang F, Zhao W, Yan S and Wang Y (2012) Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus, Endocrine Journal, 10.1507/endocrj.EJ12-0092, 59:11, (1031-1039), . Aronow W and Frishman W (2011) Physiologic Changes in Cardiac Function with Aging Principles and Practice of Geriatric Surgery, 10.1007/978-1-4419-6999-6_50, (621-633), . Conti E, Musumeci M, De Giusti M, Dito E, Mastromarino V, Autore C and Volpe M (2011) IGF-1 and atherothrombosis: relevance to pathophysiology and therapy, Clinical Science, 10.1042/CS20100400, 120:9, (377-402), Online publication date: 1-May-2011. Khan M, Akhtar S, Mohsin S, N. Khan S and Riazuddin S (2011) Growth Factor Preconditioning Increases the Function of Diabetes-Impaired Mesenchymal Stem Cells, Stem Cells and Development, 10.1089/scd.2009.0397, 20:1, (67-75), Online publication date: 1-Jan-2011. Madonna R, Renna F, Cellini C, Cotellese R, Picardi N, Francomano F, Innocenti P and De Caterina R (2010) Age-dependent impairment of number and angiogenic potential of adipose tissue-derived progenitor cells, European Journal of Clinical Investigation, 10.1111/j.1365-2362.2010.02384.x, 41:2, (126-133), Online publication date: 1-Feb-2011. Gläser S, Friedrich N, Ewert R, Schäper C, Nauck M, Dörr M, Völzke H, Felix S, Krebs A, Wallaschofski H and Koch B (2009) Association between Serum Insulin-Like Growth Factor (IGF) I and IGF Binding Protein-3 and Lung Function, The Journal of Clinical Endocrinology & Metabolism, 10.1210/jc.2008-2662, 94:7, (2452-2458), Online publication date: 1-Jul-2009. Li M, Naqvi N, Yahiro E, Liu K, Powell P, Bradley W, Martin D, Graham R, Dell'Italia L and Husain A (2008) c-kit Is Required for Cardiomyocyte Terminal Differentiation, Circulation Research, 102:6, (677-685), Online publication date: 28-Mar-2008. Karbownik-Lewinska M, Kokoszko A, Lewandowski K, Shalet S and Lewinski A (2008) GH replacement reduces increased lipid peroxidation in GH-deficient adults, Clinical Endocrinology, 10.1111/j.1365-2265.2007.03142.x, 68:6, (957-964), Online publication date: 1-Jun-2008. Hinkal G and Donehower L (2008) How does suppression of IGF-1 signaling by DNA damage affect aging and longevity?, Mechanisms of Ageing and Development, 10.1016/j.mad.2008.02.005, 129:5, (243-253), Online publication date: 1-May-2008. Hsu C, Odewale I, Alcendor R and Sadoshima J (2008) Sirt1 protects the heart from aging and stress, bchm, 10.1515/BC.2008.032, 389:3, (221-231), Online publication date: 1-Mar-2008. McMullen J (2008) ROLE OF INSULIN-LIKE GROWTH FACTOR 1 AND PHOSPHOINOSITIDE 3-KINASE IN A SETTING OF HEART DISEASE, Clinical and Experimental Pharmacology and Physiology, 10.1111/j.1440-1681.2007.04873.x, 35:3, (349-354), Online publication date: 1-Mar-2008. Thum T, Hoeber S, Froese S, Klink I, Stichtenoth D, Galuppo P, Jakob M, Tsikas D, Anker S, Poole-Wilson P, Borlak J, Ertl G and Bauersachs J (2007) Age-Dependent Impairment of Endothelial Progenitor Cells Is Corrected by Growth Hormone Mediated Increase of Insulin-Like Growth Factor-1, Circulation Research, 100:3, (434-443), Online publication date: 16-Feb-2007.Ballard V and Edelberg J (2007) Stem Cells and the Regeneration of the Aging Cardiovascular System, Circulation Research, 100:8, (1116-1127), Online publication date: 27-Apr-2007.Alcendor R, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner S and Sadoshima J (2007) Sirt1 Regulates Aging and Resistance to Oxidative Stress in the Heart, Circulation Research, 100:10, (1512-1521), Online publication date: 25-May-2007.Rota M, Hosoda T, De Angelis A, Arcarese M, Esposito G, Rizzi R, Tillmanns J, Tugal D, Musso E, Rimoldi O, Bearzi C, Urbanek K, Anversa P, Leri A and Kajstura J (2007) The Young Mouse Heart Is Composed of Myocytes Heterogeneous in Age and Function, Circulation Research, 101:4, (387-399), Online publication date: 17-Aug-2007. MARÍN-GARCÍA J (2007) The Aging Heart: A Post-Genomic Appraisal Post-Genomic Cardiology, 10.1016/B978-012373698-7/50019-X, (579-616), . Li Q and Ren J (2007) Influence of cardiac-specific overexpression of insulin-like growth factor 1 on lifespan and aging-associated changes in cardiac intracellular Ca2+ homeostasis, protein damage and apoptotic protein expression, Aging Cell, 10.1111/j.1474-9726.2007.00343.x, 6:6, (799-806) Rosenthal N, Winn N and Santini M (2007) IGF-1, Muscle Progenitors, and Heart Failure Cardiovascular Regeneration and Stem Cell Therapy, 10.1002/9780470988909.ch16, (149-158) Rosenthal N, Santini M and Musarò A (2017) Growth Factor Enhancement of Cardiac Regeneration, Cell Transplantation, 10.3727/000000006783982287, 15:1_suppl, (41-45), Online publication date: 1-Jan-2006. Rota M, Goichberg P, Anversa P and Leri A (2015) Aging Effects on Cardiac Progenitor Cell Physiology Comprehensive Physiology, 10.1002/cphy.c140082, (1775-1814) Evans L and Ferguson B (2018) Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure, Nutrients, 10.3390/nu10081120, 10:8, (1120) Türkog˘lu N, Kızılbey K and Aydınog˘lu A (2016) Tissue Engineering, Cardiac: Biomaterials, Stem Cells, and Biomolecules Encyclopedia of Biomedical Polymers and Polymeric Biomaterials, 10.1081/E-EBPP-120050807, (7933-7956) Angelini F, Pagano F, Bordin A, Picchio V, De Falco E and Chimenti I (2017) Getting Old through the Blood: Circulating Molecules in Aging and Senescence of Cardiovascular Regenerative Cells, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2017.00062, 4 Murphy A, Vyavahare S, Kumar S, Lee T, Sharma A, Adusumilli S, Hamrick M, Isales C and Fulzele S (2022) Dietary interventions and molecular mechanisms for healthy musculoskeletal aging, Biogerontology, 10.1007/s10522-022-09970-1 September 2, 2005Vol 97, Issue 5 Advertisement Article InformationMetrics https://doi.org/10.1161/01.RES.0000182212.09147.56PMID: 16141115 Originally publishedSeptember 2, 2005 Keywordsskeletal and cardiac muscle regenerationIGF-1stem cellsPDF download Advertisement
Referência(s)